A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Address: Division of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Tom Baker Cancer Centre, Calgary, AB, Canada.; Division of Hematology, University of Alberta, Edmonton, AB, Canada.; Jewish General Hospital, Montréal, QC, Canada.; St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.; Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.; CancerCare Manitoba, Winnipeg, MB, Canada.; Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada.; Centre Hospitalier Universitaire Dr. Georges-L.-Dumont, Moncton, NB, Canada.; Division of Hematology, Leukemia/Bone Marrow Transplant Program of BC, BC Cancer, University of British Columbia, Vancouver, BC, Canada.; Division of Hematology, Dalhousie University, Halifax, NS, Canada.; McGill University Health Centre, Montréal, QC, Canada.; CHU de Québec, Hôpital de l'Enfant-Jésus, Centre Universitaire d'Hématologie et d'Oncologie de Québec, Québec, QC, Canada.; Celgene Inc., a Bristol-Myers Squibb Company, Mississauga, ON, Canada.; Value and Evidence Division, Marketing & Market Access, EVERSANA™, Sydney, NS, Canada.; Bristol Myers Squibb, Princeton, NJ, USA.